Welcome to the UPF Digital Repository

The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice

Show simple item record

dc.contributor.author Ritschka, Birgit,1985-
dc.contributor.author Knauer-Meyer, Tania
dc.contributor.author Sampaio Gonçalves, Daniel
dc.contributor.author Mas, Alba
dc.contributor.author Plassat, Jean-Luc
dc.contributor.author Durik, Matej
dc.contributor.author Jacobs, Hugues
dc.contributor.author Pedone, Elisa, 1985-
dc.contributor.author Di Vicino, Umberto
dc.contributor.author Cosma, Maria Pia, 1970-
dc.contributor.author Keyes, William M., 1973-
dc.date.accessioned 2020-05-19T10:24:42Z
dc.date.available 2020-05-19T10:24:42Z
dc.date.issued 2020
dc.identifier.citation Ritschka B, Knauer-Meyer T, Gonçalves DS, Mas A, Plassat JL, Durik M et al. The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice. Genes Dev. 2020 Apr 1; 34(7-8): 489-494. DOI: 10.1101/gad.332643.119
dc.identifier.issn 0890-9369
dc.identifier.uri http://hdl.handle.net/10230/44600
dc.description.abstract Young mammals possess a limited regenerative capacity in some tissues, which is lost upon maturation. We investigated whether cellular senescence might play a role in such loss during liver regeneration. We found that following partial hepatectomy, the senescence-associated genes p21, p16Ink4a, and p19Arf become dynamically expressed in different cell types when regenerative capacity decreases, but without a full senescent response. However, we show that treatment with a senescence-inhibiting drug improves regeneration, by disrupting aberrantly prolonged p21 expression. This work suggests that senescence may initially develop from heterogeneous cellular responses, and that senotherapeutic drugs might be useful in promoting organ regeneration.
dc.description.sponsorship Work in the Keyes lab was funded in part by grants from the Spanish Ministry for Economy and Competitiveness (SAF2013-49082-P), La Fondation Recherche Medicale (FRM) (AJE20160635985), Fondation ARC (PJA20181208104), IDEX Attractivité-University of Strasbourg (IDEX2017), and La Fondation Schlumberger pour l'Education et la Recherche (FSER) (FSER 19-Year 2018), and ANR (ANR-19-CE13-0023-03). Work was also supported by grant ANR-10-LABX-0030-INRT, a French State fund managed by the Agence Nationale de la Recherche under the frame program Investissements d'Avenir (ANR-10-IDEX-0002-02)
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Cold Spring Harbor Laboratory Press (CSHL Press)
dc.rights Published originally by Cold Spring Harbor Laboratory Press at http://dx.doi.org/10.1101/gad.332643.119. Beginning six months from the full-issue publication date, articles are distributed under the Creative Commons Attribution-Non-Commercial 4.0 International License (CC-BY-NC), as described at http://creativecommons.org/licenses/by-nc/4.0/. This license permits non-commercial use, including reproduction, adaptation, and distribution of the article provided the original author and source are credited
dc.subject.other Fetge -- Regeneració
dc.subject.other Cèl·lules hepàtiques
dc.subject.other Envelliment
dc.subject.other Senilítics
dc.title The senotherapeutic drug ABT-737 disrupts aberrant p21 expression to restore liver regeneration in adult mice
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1101/gad.332643.119
dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2013-49082-P
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking